Bank of America Initiates Coverage on Supernus with Buy Rating
Yahoo Finance ·
Bank of America has initiated coverage of Supernus Pharmaceuticals (NASDAQ:SUPN) with a buy rating and a $47 price target, highlighting enhanced earnings potential following its merger with Indivior. The combined company boasts an expanded neurology and psychiatry portfolio, with management projecting 2027 revenue of approximately $2.5 billion and EBITDA of $1.2 billion. Bank of America notes that Supernus currently trades at 5.5 times its estimated 2027 EBITDA, representing a significant discount compared to pharmaceutical peers. Key growth catalysts include Sublocade, Qelbree, Onapgo, and Zurzuvae. Furthermore, the firm estimates modest leverage with net debt at 0.8 times EBITDA, pointing to strong debt repayment capacity or potential future acquisitions.
AI 시장 분석
Bank of America (BoA) evaluated Supernus Pharmaceuticals as undervalued relative to its value through its merger with Indivior, issuing a Buy rating and a price target of $47. The combined entity is projected to diversify its CNS disease treatment portfolio and achieve $2.5 billion in revenue and $1.2 billion in EBITDA by 2027. Investors should focus on the merger synergies and the 2027 financial guidance.
상승 영향
- Biotech — Bank of America issued a Buy rating and a $47 price target based on the strengthened CNS treatment portfolio from the Supernus-Indivior merger and a 2027 revenue projection of $2.5 billion.
DYAX 전담 분석
According to BoA's analysis, the combined entity is trading at a low multiple compared to peers (5.5x EBITDA) as of 2027, leaving sufficient upside potential. Core products such as Sublocade and Qelbree are driving growth, and the merger maintains a stable leverage ratio, ensuring high financial health.
In the bull case, the 2027 guidance could exceed market expectations, leading to a rerating of the valuation multiple to industry average levels. Conversely, in the bear case, earnings visibility could be impaired due to persistent supply constraints for Onapgo or intensifying competition, requiring close monitoring of product adoption rates and the achievement of cost-cutting targets.
AI가 생성한 분석으로 투자 자문이 아닙니다.
DYAX Investor Sentiment
Bullish (Long) 56% · Bearish (Short) 44%
368 participants
Related News
- Anthropic Unveils Upgraded Claude Model Ahead of IPO
- Anthropic Unveils Fable 5.2 and Mythos 5.2 AI Models Ahead of IPO
- Navigating a Nine-Month Severance at 55 and the Seven-Year Social Security Gap
- Tesla Gains 5% Amid Cybertruck Refund Warnings While Lucid and Rivian Advance
- Morgan Stanley Rises 4% on Vinyl Equity Transaction to Capture IPO Wealth, Alongside Goldman Sachs and JPMorgan Gains
- Exxon Mobil Shares Dip 0.31% as Crude Oil Prices Approach $87
